NASDAQ:MLNT Melinta Therapeutics (MLNT) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free MLNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.35▼$0.5052-Week Range N/AVolumeN/AAverage Volume713,628 shsMarket Capitalization$6.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Melinta Therapeutics alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Melinta Therapeutics Stock (NASDAQ:MLNT)Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. MLNT Stock News HeadlinesApril 23, 2024 | seekingalpha.comSWTX SpringWorks Therapeutics, Inc.February 28, 2024 | msn.comFDA Requests Additional Data for Venatorx and Melinta's Antibiotic CombinationApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.February 27, 2024 | msn.comPromising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIsFebruary 23, 2024 | finance.yahoo.comVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-TaniborbactamDecember 5, 2023 | msn.comCidara, Melinta announce publication of Rezzayo data in medical journalNovember 9, 2023 | finance.yahoo.comMelinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.October 11, 2023 | finance.yahoo.comMelinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023April 25, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.October 2, 2023 | uk.finance.yahoo.comMelinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)September 26, 2023 | thestreet.comMelinta Therapeutics, Inc.May 15, 2023 | finance.yahoo.comMelinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in CanadaMarch 1, 2023 | seekingalpha.comCidara Therapeutics Sheds Skin, Shifts To ImmunotherapyFebruary 24, 2023 | finance.yahoo.comBiVictriX Therapeutics reports "really exciting" BCX001 dataOctober 20, 2022 | technews.tmcnet.comOptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired EventJuly 27, 2022 | finance.yahoo.comMelinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.October 25, 2021 | finance.yahoo.comMelinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug DevelopmentSeptember 20, 2021 | apnews.comMelinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)See More Headlines Receive MLNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2019Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MLNT CUSIP15130J10 CIK1461993 Webwww.melinta.com Phone908-617-1309FaxN/AEmployees290Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-157,190,000.00 Net Margins-393.39% Pretax MarginN/A Return on Equity-101.29% Return on Assets-28.68% Debt Debt-to-Equity Ratio1.11 Current Ratio1.03 Quick Ratio0.72 Sales & Book Value Annual Sales$96.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$16.96 per share Price / BookN/AMiscellaneous Outstanding Shares13,750,000Free FloatN/AMarket Cap$6.88 million OptionableOptionable Beta4.16 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Erin M. Duffy (Age 51)Chief Scientific Officer & Exec. VP Mr. John H. Johnson (Age 61)CEO & Director Dr. Thomas A. SteitzCo-FounderDr. Peter B. Moore Ph.D.Co-FounderDr. William L. JorgensenCo-FounderKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXAdial PharmaceuticalsNASDAQ:ADILYumanity TherapeuticsNASDAQ:YMTXCadrenal TherapeuticsNASDAQ:CVKDProtagenic TherapeuticsNASDAQ:PTIXView All Competitors MLNT Stock Analysis - Frequently Asked Questions How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics Inc (NASDAQ:MLNT) announced its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to the consensus estimate of $15.51 million. Melinta Therapeutics had a negative trailing twelve-month return on equity of 101.29% and a negative net margin of 393.39%. When did Melinta Therapeutics' stock split? Melinta Therapeutics's stock reverse split on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Melinta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Novavax (NVAX) and Nabriva Therapeutics (NBRV). This page (NASDAQ:MLNT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
